Literature DB >> 18637800

Recent advances in the understanding of inherited sideroblastic anaemia.

Clara Camaschella1.   

Abstract

Sideroblastic anaemia includes a heterogeneous group of rare conditions, characterized by decreased haem synthesis and mitochondrial iron overload, which are diagnosed by the presence of ringed sideroblasts in the bone marrow aspirate. The most frequent form is X-linked sideroblastic anaemia, caused by mutations of delta-aminolevulinic acid synthase 2 (ALAS2), the enzyme that catalyses the first and regulatory step of haem synthesis in erythroid precursors and is post-transcriptionally controlled by the iron regulatory proteins. Impaired haem production causes variable degrees of anaemia and mitochondrial iron accumulation as ringed sideroblasts. The heterogeneity and complexity of sideroblastic anaemia is explained by an increasing number of recognized molecular defects. New forms have been recognized as being linked to the deficient function of mitochondrial proteins involved in iron-sulphur cluster biogenesis, such as ABCB7 and GLRX5, which are extremely rare but represent important biological models. Local mitochondrial iron overload is present in all sideroblastic anaemias, whereas systemic iron overload occurs only in the forms because of primary or secondary deficiency of ALAS2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637800     DOI: 10.1111/j.1365-2141.2008.07290.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

Review 1.  Structure and function of enzymes in heme biosynthesis.

Authors:  Gunhild Layer; Joachim Reichelt; Dieter Jahn; Dirk W Heinz
Journal:  Protein Sci       Date:  2010-06       Impact factor: 6.725

Review 2.  5-aminolevulinate synthase: catalysis of the first step of heme biosynthesis.

Authors:  G A Hunter; G C Ferreira
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2009-02-16       Impact factor: 1.770

3.  Need for early recognition and therapeutic guidelines of congenital sideroblastic anaemia.

Authors:  M L H Cuijpers; D J van Spronsen; P Muus; B C J Hamel; D W Swinkels
Journal:  Int J Hematol       Date:  2011-06-08       Impact factor: 2.490

4.  Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts.

Authors:  Hong Ye; Suh Young Jeong; Manik C Ghosh; Gennadiy Kovtunovych; Laura Silvestri; Danilo Ortillo; Naoya Uchida; John Tisdale; Clara Camaschella; Tracey A Rouault
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

5.  Congenital sideroblastic anemia of a Saudi child.

Authors:  Muneer H ALBagshi; Somaya H Saloma; Hassan M Albagshi
Journal:  Sudan J Paediatr       Date:  2017

6.  Hemosiderosis causing liver cirrhosis in a patient with Hb S/beta thalassemia and no other known causes of hepatic disease.

Authors:  C Demosthenous; G Rizos; E Vlachaki; G Tzatzagou; M Gavra
Journal:  Hippokratia       Date:  2017 Jan-Mar       Impact factor: 0.471

Review 7.  Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis.

Authors:  Achille Iolascon; Luigia De Falco; Carole Beaumont
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

8.  Iron Loading and Overloading due to Ineffective Erythropoiesis.

Authors:  Toshihiko Tanno; Jeffery L Miller
Journal:  Adv Hematol       Date:  2010-05-11

9.  Biophysical characterization of the iron in mitochondria from Atm1p-depleted Saccharomyces cerevisiae.

Authors:  Ren Miao; Hansoo Kim; Uma Mahendra Kumar Koppolu; E Ann Ellis; Robert A Scott; Paul A Lindahl
Journal:  Biochemistry       Date:  2009-10-13       Impact factor: 3.162

10.  X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).

Authors:  David F Bishop; Vassili Tchaikovskii; A Victor Hoffbrand; Marie E Fraser; Steven Margolis
Journal:  J Biol Chem       Date:  2012-06-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.